Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer
|ClinicalTrials.gov Identifier: NCT01050842|
Recruitment Status : Completed
First Posted : January 15, 2010
Last Update Posted : March 23, 2017
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Selective estrogen receptor modulators, such as raloxifene, may work together with bicalutamide to stop the growth of prostate cancer.
PURPOSE: This clinical trial studies giving bicalutamide and raloxifene together in treating patients with metastatic or hormone-refractory prostate cancer.
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer Adenocarcinoma of the Prostate Hormone-resistant Prostate Cancer Stage IV Prostate Cancer||Drug: bicalutamide Drug: raloxifene Procedure: quality-of-life assessment||Early Phase 1|
I. To describe the 6-month progression-free survival rate, progression-free survival, and overall survival of patients receiving bicalutamide and raloxifene.
II. To describe the adverse event profile of combined treatment with bicalutamide and raloxifene (adverse events graded using the NCI CTCAE version 3.0).
III. To describe the quality of life of patients receiving bicalutamide and raloxifene.
OUTLINE: Patients receive oral bicalutamide and oral raloxifene on days 1-28. Treatment repeats for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3-6 months for up to 3 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||18 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pilot Trial to Evaluate the Safety and Efficacy of the Administration of Bicalutamide (Casodex TM) Per Day in Combination With Raloxifene (Evista TM) Per Day in Patients With Hormone Refractory Prostate Cancer|
|Actual Study Start Date :||February 2010|
|Primary Completion Date :||May 2012|
|Study Completion Date :||October 4, 2012|
Experimental: Arm I
Patients receive oral bicalutamide and oral raloxifene on days 1-28.
Other Names:Drug: raloxifene
Other Names:Procedure: quality-of-life assessment
Other Name: quality of life assessment
- Progression-free survival rate [ Time Frame: 6 months ]
- Adverse events of combined treatment with bicalutamide and raloxifene as measured by CTCAE version 3.0
- Quality of life as assessed by Linear Analogue Self Assessment (LASA6) and the Hormonal Domain scale of the Expanded Prostate Cancer Index Composite (EPIC-H) survey
- Survival time
- Measurable or evaluable disease as assessed by RECIST
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01050842
|United States, Arizona|
|Mayo Clinic In Arizona|
|Scottsdale, Arizona, United States, 85259|
|Study Chair:||Erik P. Castle, M.D.||Mayo Clinic|